{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:43Z","timestamp":1780987963241,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jgo.2026.102932","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:35:07Z","timestamp":1772742907000},"page":"102932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75\u00a0years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty"],"prefix":"10.1016","volume":"17","author":[{"given":"Patrick M.","family":"Reagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Magnuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2026.102932_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.102932_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100670","article-title":"Older adults in hematologic malignancy trials: representation, barriers to participation and strategies for addressing underrepresentation","volume":"43","author":"Kanapuru","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.jgo.2026.102932_bb0015","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.jgo.2026.102932_bb0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","article-title":"Geriatric assessment in older adults with non-Hodgkin lymphoma: a Young International Society of Geriatric Oncology (YSIOG) review paper","volume":"13","author":"Akhtar","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102932_bb0025","first-page":"496","article-title":"Geriatric assessment for the practicing clinician: the why, what, and how","volume":"74","author":"Magnuson","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"60","key":"10.1016\/j.jgo.2026.102932_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jncimonographs\/lgac020","article-title":"Preface: engaging older adults in cancer clinical trials conducted in the National Cancer Institute clinical trials network: opportunities to enhance accrual","volume":"2022","author":"St. Germain","year":"2022","journal-title":"JNCI Monogr"},{"issue":"60","key":"10.1016\/j.jgo.2026.102932_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jncimonographs\/lgac021","article-title":"Integrating geriatric assessment measures into National Cancer Institute clinical trials","volume":"2022","author":"Magnuson","year":"2022","journal-title":"JNCI Monogr"},{"issue":"7","key":"10.1016\/j.jgo.2026.102932_bb0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"24","key":"10.1016\/j.jgo.2026.102932_bb0045","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1002\/cncr.30269","article-title":"Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.jgo.2026.102932_bb0050","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102932_bb0055","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer","volume":"39","author":"Magnuson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10314","key":"10.1016\/j.jgo.2026.102932_bb0060","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jgo.2026.102932_bb0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.102932_bb0070","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jgo.2026.102932_bb0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus Lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102932_bb0080","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jgo.2026.102932_bb0085","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jgo.2026.102932_bb0090","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.2021011894","article-title":"Phase 1\/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma","volume":"139","author":"Ward","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jgo.2026.102932_bb0095","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102932_bb0100","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.jgo.2026.102932_bb0105","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2026.102932_bb0110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jgo.2026.102932_bb0115","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2026.102932_bb0120","series-title":"Measuring Functioning and Well-being; The Medical Outcomes Study Approach","first-page":"86","article-title":"Physical functioning measures","author":"Stewart","year":"1992"},{"issue":"5","key":"10.1016\/j.jgo.2026.102932_bb0125","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1532-5415.2005.53269.x","article-title":"Simplifying detection of cognitive impairment: comparison of the Mini-cog and Mini-mental state examination in a multiethnic sample","volume":"53","author":"Borson","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.jgo.2026.102932_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jgo.2021.07.011","article-title":"Relationship between cognitive functioning and frailty in older breast cancer survivors","volume":"13","author":"Ahles","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2026.102932_bb0135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgo.2026.102932_bb0140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"26","key":"10.1016\/j.jgo.2026.102932_bb0145","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jgo.2026.102932_bb0150","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jgo.2026.102932_bb0155","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102932_bb0160","first-page":"1","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B cell lymphoma: a prospective multicenter evaluation on 173 patients by the lymphoma Italian foundation (FIL)","author":"Tucci","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jgo.2026.102932_bb0165","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2026.102932_bb0170","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jgo.2026.102932_bb0175","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2026.102932_bb0180","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1080\/10428194.2019.1639172","article-title":"Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation","volume":"60","author":"Loh","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682600086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682600086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:49:06Z","timestamp":1774885746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940682600086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S187940682600086X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102932","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75\u00a0years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102932"}}